Nurix Therapeutics (NRIX) EBITDA Margin (2019 - 2026)

Nurix Therapeutics (NRIX) has reported EBITDA Margin for 8 consecutive years, with 1041.73% the latest figure, recorded in Q2 2026.

• In Q2 2026, EBITDA Margin fell 93205.0% year-over-year to 1041.73%; the TTM figure through May 2026 stood at 982.37% (down 72162.0% YoY), while the FY2025 annual figure was 340.16%, up 5036.0% from the prior year.
• EBITDA Margin climbed to 1041.73% in Q2 2026 per NRIX's latest filing, from 1479.45% in the prior quarter.
• Across five years, EBITDA Margin topped out at 87.25% in Q2 2023 and bottomed at 1479.45% in Q1 2026.
• Historically, EBITDA Margin has averaged 515.13% across 5 years, with a median of 417.18% in 2022.
• Annual changes were most pronounced in 2023 — EBITDA Margin jumped 41877 bps — and 2026, when it plunged 113878 bps.
• Nurix Therapeutics' EBITDA Margin stood at 717.82% in 2022, then surged by 58 bps to 299.06% in 2023, then plunged by 63 bps to 486.73% in 2024, then declined by 26 bps to 612.03% in 2025, then slumped by 70 bps to 1041.73% in 2026.
• Business Quant data shows NRIX's EBITDA Margin at 1041.73% in Q2 2026, 1479.45% in Q1 2026, and 612.03% in Q4 2025.